PMC:7555630 / 8351-9736 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T9","span":{"begin":175,"end":179},"obj":"Body_part"},{"id":"T10","span":{"begin":610,"end":616},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma264279"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":175,"end":179},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T78","span":{"begin":94,"end":102},"obj":"Disease"},{"id":"T79","span":{"begin":104,"end":140},"obj":"Disease"},{"id":"T80","span":{"begin":104,"end":116},"obj":"Disease"},{"id":"T81","span":{"begin":118,"end":140},"obj":"Disease"},{"id":"T82","span":{"begin":142,"end":155},"obj":"Disease"},{"id":"T84","span":{"begin":157,"end":165},"obj":"Disease"},{"id":"T85","span":{"begin":175,"end":187},"obj":"Disease"},{"id":"T86","span":{"begin":656,"end":664},"obj":"Disease"},{"id":"T87","span":{"begin":817,"end":825},"obj":"Disease"},{"id":"T88","span":{"begin":875,"end":886},"obj":"Disease"},{"id":"T89","span":{"begin":971,"end":988},"obj":"Disease"}],"attributes":[{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0001302"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0002118"},{"id":"A83","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005240"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0045057"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0001627"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0005468"},{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0005395"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T37","span":{"begin":175,"end":179},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T38","span":{"begin":175,"end":179},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T39","span":{"begin":283,"end":285},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T40","span":{"begin":789,"end":790},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T41","span":{"begin":846,"end":848},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":433,"end":438},"obj":"Chemical"},{"id":"T8","span":{"begin":1213,"end":1231},"obj":"Chemical"},{"id":"T9","span":{"begin":1249,"end":1260},"obj":"Chemical"},{"id":"T10","span":{"begin":1293,"end":1303},"obj":"Chemical"},{"id":"T11","span":{"begin":1353,"end":1363},"obj":"Chemical"},{"id":"T12","span":{"begin":1374,"end":1383},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_40519"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_2618"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_64312"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T53","span":{"begin":104,"end":116},"obj":"Phenotype"},{"id":"T54","span":{"begin":118,"end":140},"obj":"Phenotype"},{"id":"T55","span":{"begin":167,"end":187},"obj":"Phenotype"},{"id":"T56","span":{"begin":635,"end":643},"obj":"Phenotype"},{"id":"T57","span":{"begin":656,"end":664},"obj":"Phenotype"},{"id":"T58","span":{"begin":666,"end":680},"obj":"Phenotype"},{"id":"T59","span":{"begin":685,"end":697},"obj":"Phenotype"},{"id":"T60","span":{"begin":817,"end":825},"obj":"Phenotype"},{"id":"T61","span":{"begin":875,"end":886},"obj":"Phenotype"},{"id":"T62","span":{"begin":925,"end":950},"obj":"Phenotype"},{"id":"T63","span":{"begin":971,"end":988},"obj":"Phenotype"},{"id":"T64","span":{"begin":1031,"end":1051},"obj":"Phenotype"}],"attributes":[{"id":"A53","pred":"hp_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A54","pred":"hp_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A55","pred":"hp_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/HP_0006528"},{"id":"A56","pred":"hp_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/HP_0001254"},{"id":"A57","pred":"hp_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/HP_0031258"},{"id":"A58","pred":"hp_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/HP_0000738"},{"id":"A59","pred":"hp_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/HP_0031843"},{"id":"A60","pred":"hp_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/HP_0000726"},{"id":"A61","pred":"hp_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/HP_0002615"},{"id":"A62","pred":"hp_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/HP_0100022"},{"id":"A63","pred":"hp_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/HP_0100022"},{"id":"A64","pred":"hp_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/HP_0003324"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T56","span":{"begin":0,"end":263},"obj":"Sentence"},{"id":"T57","span":{"begin":264,"end":452},"obj":"Sentence"},{"id":"T58","span":{"begin":453,"end":544},"obj":"Sentence"},{"id":"T59","span":{"begin":545,"end":755},"obj":"Sentence"},{"id":"T60","span":{"begin":756,"end":826},"obj":"Sentence"},{"id":"T61","span":{"begin":827,"end":951},"obj":"Sentence"},{"id":"T62","span":{"begin":952,"end":1136},"obj":"Sentence"},{"id":"T63","span":{"begin":1137,"end":1189},"obj":"Sentence"},{"id":"T64","span":{"begin":1190,"end":1261},"obj":"Sentence"},{"id":"T65","span":{"begin":1262,"end":1385},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"284","span":{"begin":13,"end":21},"obj":"Species"},{"id":"285","span":{"begin":273,"end":281},"obj":"Species"},{"id":"286","span":{"begin":571,"end":579},"obj":"Species"},{"id":"287","span":{"begin":836,"end":844},"obj":"Species"},{"id":"288","span":{"begin":1011,"end":1019},"obj":"Species"},{"id":"289","span":{"begin":1121,"end":1129},"obj":"Species"},{"id":"290","span":{"begin":1149,"end":1157},"obj":"Species"},{"id":"291","span":{"begin":1195,"end":1203},"obj":"Species"},{"id":"292","span":{"begin":1266,"end":1274},"obj":"Species"},{"id":"293","span":{"begin":1213,"end":1231},"obj":"Chemical"},{"id":"294","span":{"begin":1249,"end":1260},"obj":"Chemical"},{"id":"295","span":{"begin":1293,"end":1303},"obj":"Chemical"},{"id":"296","span":{"begin":1353,"end":1363},"obj":"Chemical"},{"id":"297","span":{"begin":1374,"end":1383},"obj":"Chemical"},{"id":"298","span":{"begin":94,"end":102},"obj":"Disease"},{"id":"299","span":{"begin":104,"end":116},"obj":"Disease"},{"id":"300","span":{"begin":118,"end":140},"obj":"Disease"},{"id":"301","span":{"begin":142,"end":155},"obj":"Disease"},{"id":"302","span":{"begin":157,"end":165},"obj":"Disease"},{"id":"303","span":{"begin":175,"end":187},"obj":"Disease"},{"id":"304","span":{"begin":635,"end":643},"obj":"Disease"},{"id":"305","span":{"begin":656,"end":664},"obj":"Disease"},{"id":"306","span":{"begin":666,"end":680},"obj":"Disease"},{"id":"307","span":{"begin":685,"end":697},"obj":"Disease"},{"id":"308","span":{"begin":817,"end":825},"obj":"Disease"},{"id":"309","span":{"begin":875,"end":886},"obj":"Disease"},{"id":"310","span":{"begin":971,"end":988},"obj":"Disease"},{"id":"311","span":{"begin":1043,"end":1051},"obj":"Disease"}],"attributes":[{"id":"A284","pred":"tao:has_database_id","subj":"284","obj":"Tax:9606"},{"id":"A285","pred":"tao:has_database_id","subj":"285","obj":"Tax:9606"},{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"Tax:9606"},{"id":"A287","pred":"tao:has_database_id","subj":"287","obj":"Tax:9606"},{"id":"A288","pred":"tao:has_database_id","subj":"288","obj":"Tax:9606"},{"id":"A289","pred":"tao:has_database_id","subj":"289","obj":"Tax:9606"},{"id":"A290","pred":"tao:has_database_id","subj":"290","obj":"Tax:9606"},{"id":"A291","pred":"tao:has_database_id","subj":"291","obj":"Tax:9606"},{"id":"A292","pred":"tao:has_database_id","subj":"292","obj":"Tax:9606"},{"id":"A293","pred":"tao:has_database_id","subj":"293","obj":"MESH:D006886"},{"id":"A294","pred":"tao:has_database_id","subj":"294","obj":"MESH:D053139"},{"id":"A295","pred":"tao:has_database_id","subj":"295","obj":"MESH:D000218"},{"id":"A296","pred":"tao:has_database_id","subj":"296","obj":"MESH:D000547"},{"id":"A297","pred":"tao:has_database_id","subj":"297","obj":"MESH:D008559"},{"id":"A298","pred":"tao:has_database_id","subj":"298","obj":"MESH:C000657245"},{"id":"A299","pred":"tao:has_database_id","subj":"299","obj":"MESH:D006973"},{"id":"A300","pred":"tao:has_database_id","subj":"300","obj":"MESH:D002318"},{"id":"A301","pred":"tao:has_database_id","subj":"301","obj":"MESH:D007674"},{"id":"A302","pred":"tao:has_database_id","subj":"302","obj":"MESH:D003920"},{"id":"A303","pred":"tao:has_database_id","subj":"303","obj":"MESH:D008171"},{"id":"A304","pred":"tao:has_database_id","subj":"304","obj":"MESH:D053609"},{"id":"A305","pred":"tao:has_database_id","subj":"305","obj":"MESH:D003693"},{"id":"A306","pred":"tao:has_database_id","subj":"306","obj":"MESH:D006212"},{"id":"A308","pred":"tao:has_database_id","subj":"308","obj":"MESH:D003704"},{"id":"A309","pred":"tao:has_database_id","subj":"309","obj":"MESH:D007022"},{"id":"A310","pred":"tao:has_database_id","subj":"310","obj":"MESH:D009069"},{"id":"A311","pred":"tao:has_database_id","subj":"311","obj":"MESH:D018908"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Twenty-eight patients (78%) had at least one of six comorbidities associated with more severe COVID-19 (hypertension, cardiovascular disease, renal disease, diabetes, chronic lung disease, or immunosuppression), with the majority having more than one risk factor. Thirteen patients (36%) lived in their own home, while twenty-three (64%) were at extended care facilities: nursing home (n = 17), assisted living facility (n = 5), and group home (n = 1). Their presentation, clinical course, management, and outcome are also presented in Table 1. Of interest, twenty-seven patients (75%) exhibited alteration in mental status (including lethargy, confusion, delirium, hallucinations, or bradyphrenia), and in twenty-two (61%), it was the presenting symptom. Of these, only fifteen (56%) had a pre-existing diagnosis of dementia. Thirteen patients (36%) were documented to have hypotension, and fifteen (42%) were noted to have abnormalities of movement. Worsening of their movement disorder was reported by seven patients (19%), and generalized weakness or worsening mobility were noted as the presenting symptom by eleven patients (31%). Twenty-four patients (67%) required hospitalization. Nine patients received hydroxychloroquine and two received oseltamivir. Six patients were receiving an adamantane as part of their neurologic management (three on amantadine, three on memantine)."}